Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Orally active dual NK1/NK2 antagonist from Merck & Co.

Sep. 6, 1996

SmithKline Beecham stresses dual PDE IV and TNF production inhibitors

Sep. 6, 1996

Bock Pharmacal introduces antihistamine-free cough syrup

Sep. 6, 1996

Clearance for Schering-Plough's extended-release Claritin-D

Sep. 6, 1996

SKB claims NK3 antagonists for pulmonary disorders

Aug. 30, 1996

SKB reports on PDE IV inhibitor research

Aug. 30, 1996

Scirex to manage IND filing for Apanol

Aug. 30, 1996

Usherdex-4 and other dextrans covered under U.S. patent

Aug. 23, 1996

Forest's Infasurf earns approvable status

Aug. 23, 1996

FR-173657: Fujisawa's bradykinin B2 antagonist

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.